3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
234
Head and Neck Neoplasms
123
Carcinoma, Non-Small-Cell Lung
78
Melanoma
73
Colorectal Neoplasms
43
Carcinoma, Renal Cell
43
Neoplasm Metastasis
35
Neoplasms
33
Triple Negative Breast Neoplasms
31
Uterine Cervical Neoplasms
30
Stomach Neoplasms
30
Carcinoma, Transitional Cell
30
Breast Neoplasms
30
Lung Neoplasms
29
Ovarian Neoplasms
28
Carcinoma, Squamous Cell
24
Pancreatic Neoplasms
23
Carcinoma
23
Esophageal Neoplasms
20
Endometrial Neoplasms
19
Oropharyngeal Neoplasms
18
Mouth Neoplasms
18
Carcinoma, Hepatocellular
18
Small Cell Lung Carcinoma
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
16
Urinary Bladder Neoplasms
13
Nasopharyngeal Carcinoma
13
Laryngeal Neoplasms
13
Prostatic Neoplasms
12
Mesothelioma
12
Interventions
pembrolizumab
1
nazartinib
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Noonan Syndrome
×
pembrolizumab
×
Head & Neck
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled